Skip to main content

Table 1 Baseline demographics and epilepsy characteristics in the 1-year pre-index period

From: Health care cost associated with the use of enzyme-inducing and non-enzyme–active antiepileptic drugs in the UK: a long-term retrospective matched cohort study

Characteristic

Overall population

Matched population

EIAED

(n = 2752)

nEAAED

(n = 2137)

p valuea

EIAED

(n = 951)

nEAAED

(n = 951)

p valuea

Age, mean (SD), years

54.2 (19.8)

45.9 (19.9)

<0.0001

47.7 (19.9)

48.0 (20.0)

0.7969

Age group, n (%)

  

<0.0001

  

1.0000

16–20

116 (4.2)

239 (11.2)

 

75 (7.9)

75 (7.9)

 

21–30

261 (9.5)

349 (16.3)

144 (15.1)

144 (15.1)

31–40

404 (14.7)

344 (16.1)

167 (17.6)

167 (17.6)

41–50

434 (15.8)

380 (17.8)

160 (16.8)

160 (16.8)

51–60

406 (14.8)

285 (13.3)

133 (14.0)

133 (14.0)

61–70

425 (15.4)

236 (11.0)

119 (12.5)

119 (12.5)

71–80

434 (15.8)

191 (8.9)

94 (9.9)

94 (9.9)

81–90

237 (8.6)

96 (4.5)

47 (4.9)

47 (4.9)

Over 90

35 (1.3)

17 (0.8)

12 (1.3)

12 (1.3)

Gender, n (%)

  

<0.0001

  

0.7130

Female

1243 (45.2)

1339 (62.7)

 

506 (53.2)

514 (54.0)

 

Male

1509 (54.8)

798 (37.3)

445 (46.8)

437 (46.0)

Germaine-Smith epilepsy-specific comorbidity index, mean score (SD)

1.0 (2.0)

0.6 (1.6)

<0.0001

0.7 (1.6)

0.7 (1.5)

0.8272

Time since first epilepsy diagnosis, years

      

Mean (SD)

4.5 (10.3)

8.5 (13.5)

<0.0001

5.8 (11.1)

6.2 (12.0)

0.4604

Median (P25–P75)

0.2 (0.1–2.5)

1.3 (0.1–10.9)

 

0.4 (0.1–5.8)

0.6 (0.1–6.3)

 

Epilepsy type, n (%)

  

0.0011

0.7202

Generalized

301 (10.9)

212 (9.9)

 

78 (8.2)

85 (8.9)

 

Partial

470 (17.1)

291 (13.6)

148 (15.6)

138 (14.5)

Unspecified

1981 (72.0)

1634 (76.5)

725 (76.2)

728 (76.6)

  1. Abbreviations: EIAED enzyme-inducing antiepileptic drug, nEAAED non-enzyme–active antiepileptic drug, P25–P75 25th to 75th percentile, SD standard deviation
  2. a t test for continuous variables, chi-square test for categorical variables